Participated · Series C · Jun 2025

Infleqtion builds a diversified portfolio of quantum technologies, including neutral-atom quantum computers, quantum optical clocks, RF receivers, inertial sensors, and the Superstaq quantum software platform. Its hardware and software are already in use by customers such as the U.S. Department of War, NASA, the U.K. government, and partners like NVIDIA. The company is expanding its government and commercial engagements, exemplified by multiple ARPA-E contracts aimed at tackling energy-related challenges. Under the new QC3 award, Infleqtion will employ its neutral-atom platform and a proprietary algorithm to search for novel high-temperature superconductors that could enable lossless power transmission. Parallel work under the ENCODE program applies quantum-enhanced methods to optimize the energy grid. Together, these projects position Infleqtion at the forefront of quantum applications in chemistry, materials science, and energy infrastructure. Although the article does not disclose revenue or user counts, the repeated selection for federal contracts highlights growing commercial traction and non-dilutive funding to support R&D.

Participated · Seed · Sep 2022

Meliora Therapeutics builds a machine-learning-driven computational platform to decipher oncology drugs' true mechanisms of action and create an industry-first MOA atlas. Its core product is an inference engine that uses "molecular fingerprints" for tens of thousands of small molecules to match compounds to mechanisms. The company has a computational prototype and has generated in‑vitro wet lab data validating dozens of compounds computationally identified as having alternate MOAs, with many showing strong potency against predicted targets. Meliora plans to expand its platform, build a proprietary data moat, select mischaracterized scaffolds as starting points for lead precision therapeutic programs, and grow its team, operations, and industry partnerships. The company was founded in September 2021 and is headquartered in Menlo Park, CA. It recently closed a seed financing to accelerate development of its proprietary platform and programs.

Participated · Seed · Jul 2022

Replay develops genomic medicine platforms, led by uCell™, an off-the-shelf hypoimmunogenic technology for making allogeneic donor-derived primary cells and iPSCs immune silent. Its toolkit also includes a high-payload HSV delivery platform (synHSV™) and a proprietary genome writing platform. Replay says uCell™ can reduce cost-of-goods, improve product volume and consistency, enable extensive genome engineering, and broaden access to cell therapies across cancer, infectious diseases, neurodegenerative diseases, and regenerative medicine. The company operates a hub-and-spoke business model that separates technology development at Replay from therapeutic development in product companies and plans to progress uCell™ through therapeutic-area-focused product companies. Replay received non-dilutive support—a $1.56 million grant from the Bill & Melinda Gates Foundation—to accelerate uCell™ development, and previously raised $55 million in seed financing in July 2022. The company is headquartered in San Diego, California and London, UK, and is led by a team of academics, entrepreneurs, and industry experts. Replay develops genome writing and delivery technologies to enable large‑payload genetic reprogramming, assembling a toolkit that includes a high‑payload HSV platform, a hypoimmunogenic platform, and a genome writing platform. The company has also established an enzyme‑writing product company that leverages its evolutionary inference machine‑learning and genome‑writing technology to optimize functionality. Replay positions these platforms to address scientific challenges limiting clinical progress and to advance genomic medicine. Its leadership team includes experienced executives and pioneers in virology and synthetic biology, and the company lists multiple academic and industry advisors and co‑founders. The article does not disclose revenue or user metrics; the only financial detail provided is the recent fundraise.

Participated · Series A · Jun 2022

Charm Therapeutics develops precision oncology treatments via a proprietary AI-driven drug discovery platform. Its lead program is a menin inhibitor targeting acute myeloid leukemia (AML). The company's candidates are designed to retain potency against known clinical resistance mutations, aiming to deliver more durable patient responses. Charm was founded by Laksh Aithani and David Baker and is based in London and Cambridge, UK. Following its Series B, the company is advancing its programs toward clinical trials. The company raised $80M in Series B financing to support these efforts. CHARM Therapeutics is a London-based 3D deep-learning biotechnology company that discovers and develops small-molecule medicines for difficult-to-drug cancer targets using its proprietary DragonFold protein-ligand co-folding platform. The company applies high-throughput protein-ligand co-folding and machine learning to identify novel molecules and accelerate preclinical discovery. CHARM leverages accelerated computing, including NVIDIA GPUs, to rapidly identify potential compounds. The recent investment from NVentures will support R&D and help fund its rapidly growing organization as it advances novel oncology programs. CHARM has raised $70 million to date and is supported by investors such as OrbiMed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, and NVIDIA. The company plans to use the funding and NVIDIA's accelerated computing platform to bring potential new therapies to patients faster. Charm Therapeutics built DragonFold, which it describes as the first protein–ligand co‑folding algorithm for predicting how proteins and potential drugs interact. The company applies machine learning to simulate complex protein interactions and aims to screen vastly larger sets of candidate molecules while reducing wet‑lab screening. Early‑stage funding was used to build the initial model, which has been validated in‑silico. Over the coming quarters Charm plans to validate DragonFold experimentally and use the platform to discover medicines. The company intends the product primarily for internal use so its scientists can identify drug candidates that Charm owns 100% of the rights to. Leadership and technical credibility include co‑founder and CEO Laskh Aithani and co‑founder David Baker, with Sergey Bartunov as director of AI and Sarah Skerratt as head of drug discovery.

Participated · Seed · Feb 2022

Adaptyv Biosystems operates an automated, cloud-accessible laboratory that closes the critical “design-test-learn” loop for AI-driven protein engineering. Its platform performs high-throughput experimental assays to verify the function of proteins proposed by computational models, addressing the cost and accessibility barriers that typically slow validation. In beta, the system has already tested more than 10,000 proteins in partnership with about 30 pharmaceutical and biotech teams, and in one international competition it boosted hit rates from 2.5 % to 13 % within two months. By automating wet-lab steps and streaming data back to model builders, the company aims to accelerate the creation of therapeutic and industrial proteins. With fresh capital, Adaptyv plans to broaden the menu of assays, deepen robotic automation, and launch an API that pipes experimental results directly into AI models. The company is headquartered in the Lausanne area (Épalinges) and positions itself as an infrastructure provider for the growing protein-design ecosystem.